Efficacy and Safety of Deucravacitinib for Psoriasis: A Multicenter Real-World Analysis Focusing on Scalp Outcomes—IL PSO (Italian Landscape Psoriasis) - Scorecard - MDSpire

Efficacy and Safety of Deucravacitinib for Psoriasis: A Multicenter Real-World Analysis Focusing on Scalp Outcomes—IL PSO (Italian Landscape Psoriasis)

  • By

  • Luciano Ibba

  • Sara Di Giulio

  • Piergiorgio Malagoli

  • Anna Balato

  • Angelo Valerio Marzano

  • Matteo Megna

  • Diego Orsini

  • Lidia Sacchelli

  • Santo Raffaele Mercuri

  • Emanuele Trovato

  • Serena Giacalone

  • Alexia Pedron

  • Marzia Caproni

  • Edoardo Cammarata

  • Aldo Cuccia

  • Andrea Altomare

  • Alexandra M. G. Brunasso

  • Valentina Dini

  • Simone Ribero

  • Nicola Zerbinati

  • Francesco Messina

  • Stefano Caccavale

  • Carlo G. Carrera

  • Luca Potestio

  • Viviana Lora

  • Andrea Carugno

  • Federico Bardazzi

  • Giovanni Paolino

  • Antonio Costanzo

  • Alessandra Narcisi

  • Mario Valenti

  • March 16, 2026

  • 0 min

Share

Clinical Scorecard: Efficacy and Safety of Deucravacitinib for Psoriasis: A Multicenter Real-World Analysis Focusing on Scalp Outcomes—IL PSO (Italian Landscape Psoriasis)

At a Glance

CategoryDetail
Condition
Key MechanismsTYK2 inhibitor modulating IL-23, IL-12, and type I interferon signaling pathways (ensure accuracy).
Target Population
Care Setting

Key Highlights

  • add_data

Guideline-Based Recommendations

Diagnosis

    Management

    • S
    • p
    • e
    • c
    • i
    • f
    • y
    • w
    • h
    • i
    • c
    • h
    • c
    • o
    • n
    • v
    • e
    • n
    • t
    • i
    • o
    • n
    • a
    • l
    • t
    • r
    • e
    • a
    • t
    • m
    • e
    • n
    • t
    • s
    • a
    • r
    • e
    • r
    • e
    • f
    • e
    • r
    • e
    • n
    • c
    • e
    • d
    • .

    Monitoring & Follow-up

      Risks

        Patient & Prescribing Data

        Clinical Best Practices

        • expand_monitoring

        References

        Original Source(s)

        Efficacy and Safety of Deucravacitinib for Psoriasis: A Multicenter Real-World Analysis Focusing on Scalp Outcomes—IL PSO (Italian Landscape Psoriasis)

        • by Luciano Ibba, Sara Di Giulio, Piergiorgio Malagoli, Anna Balato, Angelo Valerio Marzano, Matteo Megna, Diego Orsini, Lidia Sacchelli, Santo Raffaele Mercuri, Emanuele Trovato, Serena Giacalone, Alexia Pedron, Marzia Caproni, Edoardo Cammarata, Aldo Cuccia, Andrea Altomare, Alexandra M. G. Brunasso, Valentina Dini, Simone Ribero, Nicola Zerbinati, Francesco Messina, Stefano Caccavale, Carlo G. Carrera, Luca Potestio, Viviana Lora, Andrea Carugno, Federico Bardazzi, Giovanni Paolino, Antonio Costanzo, Alessandra Narcisi, Mario Valenti

        • March 16, 2026

        Related Content

        Rapid Onset of Action and Quality-of-Life Improvements in Chinese Patients with Plaque Psoriasis Treated with Calcipotriol plus Betamethasone Dipropionate Aerosol Foam in a Randomized Phase 3 Trial

        Summary of Research: Apremilast Improves Skin Outcomes in Pediatric Plaque Psoriasis of Shorter Disease Duration: 52-Week Results from the SPROUT Phase 3 Trial

        AI Scribes Lag Clinicians on Note Quality

        A VHA study across 11 vendors finds AI-generated primary care notes score lower than clinician-written notes, with the largest deficits in thoroughness, organization, and usefulness